
    
      This study aims on investigating the efficacy of Dupilumab in NE patients. The primary
      endpoint is the percent change in Eczema Area and Severity Index (EASI) score from baseline
      to week 16.

      Secondary endpoints include the number of patients achieving an improvement (decrease) in
      Physician Global Assessment (PGA) by two or more points at week 16 as compared to week 0 or
      achieving an absolute PGA of 0 or 1 at Week 16, the EASI 50 score at week 16, the change from
      baseline in transepidermal waterloss (TEWL) at week 16, significant histological improvement
      at week 16, change from baseline in the reduction of the use of topical steroids at week 16,
      change form baseline in the Dermatology Life Quality Index (DLQI) at week 16, change from
      baseline in Pruritus Visual Analog Scale (VAS), change from baseline in the global
      satisfaction subscale of the treatment satisfaction questionnaire for medication (TSQM) score
      at week 16 and the safety of Dupilumab.
    
  